Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
CNBC Markets · Thu, 29 Oct 2026 14:11:41 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.”
Rule-based headline sentiment: Bullish
More Stocks headlines
CNBC Sport: Inside the scramble that moved Thursday's WNBA Finals game to 12:30 p.m. ET— CNBC MarketsDoorDash to acquire Instacart for $17 billion— CNBC MarketsCaterpillar’s stock is sinking. Here’s what that means for the Dow.— MarketWatchConsumer spending flattens out after U.S. inflation surge— MarketWatch
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →